ClinicalTrials.gg

Program

Timolol

Also written as “Timolol Maleate Gel”, “bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)” and “timolol 0.5%”.

Its studies are mostly in Glaucoma, Open-Angle · Glaucoma · Hemangioma, Capillary, led by 9 companies.

Furthest: phase 4, since Aug 13, 200823 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie80 open or runningphase 4since Aug 13, 2008Aug 13, 2008none ahead
Merck30 open or runningphase 3since Apr 12, 2005Apr 12, 2005none ahead
Santen Pharmaceutical30 open or runningphase 3since Feb 28, 2011Apr 7, 2009none ahead
Viatris30 open or runningphase 3since Sep 8, 2005Sep 8, 2005none ahead
Auson Pharmaceuticals20 open or runningphase 3since Oct 29, 2024Oct 29, 2024none ahead
Credit Valley EyeCare10 open or runningphase 4since Feb 13, 2012Feb 13, 2012none ahead
Glaukos10 open or runningphase 4since Jun 1, 2009Jun 1, 2009none ahead
Laboratorios Poen10 open or runningphase 4since Mar 30, 2023Mar 30, 2023none ahead
vistakon-pharmaceuticals10 open or runningphase 4since Dec 5, 2008Dec 5, 2008none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 9 studies since Apr 12, 2005.

  1. Jun 1, 2009Glaukos's first study: phase 4 study in Eye DiseasesNew to GlaukosGlaukos · NCT00913029 · 192 enrolled · Armenia, Austria, France and more
  2. Feb 12, 2010No phase study in Glaucoma, Open-AngleAbbVie · NCT01068964 · 235 enrolled · China
  3. Oct 5, 2010Phase 1 study in Glaucoma, Open-AngleAbbVie · NCT01215786 · 50 enrolled · United States
  4. Oct 7, 2010Phase 3 study in Glaucoma, Open-AngleAbbVie · NCT01217606 · 185 enrolled · Brazil
  5. Oct 26, 2010No phase study in GlaucomaAbbVie · NCT01229462 · 238 enrolled · China
  6. Nov 12, 2010Phase 3 study in Glaucoma, Open-AngleAbbVie · NCT01241240 · 192 enrolled · Colombia, Mexico
  7. Feb 28, 2011Phase 3 study in Ocular HypertensionSanten Pharmaceutical · NCT01306461 · 401 enrolled · Hungary
  8. Sep 12, 2011Phase 1 study in Healthy VolunteersSanten Pharmaceutical · NCT01434888 · 15 enrolled · Finland
  9. Feb 13, 2012Credit Valley EyeCare's first study: phase 4 study in GlaucomaNew to Credit Valley EyeCareCredit Valley EyeCare · NCT01535768 · 150 enrolled · Canada
  10. Jun 17, 2013Phase 4 study in GlaucomaAbbVie · NCT01881126 · 93 enrolled · Canada
  11. Mar 25, 2014Phase 4 study in GlaucomaAbbVie · NCT02097719 · 100 enrolled · United States
  12. Mar 30, 2023Laboratorios Poen's first study: phase 4 study in Glaucoma, Open-AngleNew to Laboratorios PoenLaboratorios Poen · NCT05857267 · 84 enrolled · Argentina
  13. Oct 29, 2024Auson Pharmaceuticals's first study: phase 3 study in Hemangioma, CapillaryNew to Auson PharmaceuticalsAuson Pharmaceuticals · NCT06677853 · 168 enrolled · China
  14. Jan 23, 2025Phase 1 study in Healthy SubjectsAuson Pharmaceuticals · NCT06824948 · 28 enrolled · China

TargetBeta

ADRB1 →ADRB2 →read by rule
“Beta-1 adrenergic receptor antagonist; Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Epinephrinerulenasus-pharmaphase 417

Studies

All 23 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06824948Healthy Subjects · China1CompletedAuson PharmaceuticalsDec 12, 201828
NCT06677853Hemangioma, Capillary · China3CompletedAuson PharmaceuticalsJun 21, 2022168
NCT05857267Glaucoma, Open-Angle · Argentina4CompletedLaboratorios PoenNov 4, 202484
NCT02097719Glaucoma · United States4CompletedAbbVieDec 2014100
NCT01881126Glaucoma · Canada4CompletedAbbVieOct 201493
NCT01535768Glaucoma · Canada4UNKNOWNCredit Valley EyeCareJun 2018150
NCT01434888Healthy Volunteers · Finland1CompletedSanten PharmaceuticalDec 201115
NCT01306461Ocular Hypertension · Hungary3CompletedSanten PharmaceuticalApr 2012401
NCT01241240Glaucoma, Open-Angle · Colombia, Mexico3CompletedAbbVieSep 2013192
NCT01229462Glaucoma · China–CompletedAbbVieSep 2011238
NCT01217606Glaucoma, Open-Angle · Brazil3CompletedAbbVieSep 2014185
NCT01215786Glaucoma, Open-Angle · United States1CompletedAbbVieDec 201050
NCT01068964Glaucoma, Open-Angle · China–CompletedAbbVieSep 1, 2010235
NCT00913029Eye Diseases · Armenia, Austria, France and more4CompletedGlaukosSep 2012192
NCT00879099Healthy · Finland1CompletedSanten PharmaceuticalJan 201012
NCT00856622Ocular Hypertension · Germany3CompletedViatrisJun 1999436
NCT00832377Glaucoma2CompletedMerckMar 12, 201037
NCT00804648Glaucoma, Open-Angle · United States4Completedvistakon-pharmaceuticalsDec 200830
NCT00735449Glaucoma · United States, Canada4CompletedAbbVieDec 2009204
NCT00546286Glaucoma3CompletedMerckAug 23, 2007170
NCT00277498Glaucoma, Open-Angle · United States3CompletedViatris528
NCT00159653Glaucoma, Open-Angle · United States, Canada3CompletedViatrisJun 2007500
NCT00108017Glaucoma3CompletedMerckJul 2006330

How it is read

Names in the registry

  • “Timolol Maleate Gel”, 4 entries
  • “Timolol”, 3 entries
  • “bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)”, 2 entries
  • “timolol 0.5%”, 2 entries
  • “timolol maleate”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.